Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
BriaCell Therapeutics ( (TSE:BCT) ) has issued an announcement.
BriaCell Therapeutics has successfully closed a $15 million public offering, selling 12 million units at $1.25 each, consisting of common shares and warrants. The proceeds will be used for working capital, general corporate purposes, and advancing business objectives, potentially strengthening the company’s position in the biotechnology sector.
The most recent analyst rating on (TSE:BCT) stock is a Buy with a C$15.00 price target. To see the full list of analyst forecasts on BriaCell Therapeutics stock, see the TSE:BCT Stock Forecast page.
Spark’s Take on TSE:BCT Stock
According to Spark, TipRanks’ AI Analyst, TSE:BCT is a Neutral.
BriaCell Therapeutics has a challenging financial position with no revenue and consistent losses, heavily impacting its stock score. Despite this, recent corporate developments in cancer treatment provide some potential upside. Technical indicators are mixed, and valuation concerns persist with a negative P/E ratio. The company’s reliance on external financing is a notable risk.
To see Spark’s full report on TSE:BCT stock, click here.
More about BriaCell Therapeutics
BriaCell Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care.
Average Trading Volume: 22,743
Technical Sentiment Signal: Sell
Current Market Cap: C$18.77M
For an in-depth examination of BCT stock, go to TipRanks’ Overview page.